Sequoia Sciences, Inc. Company Profile

08:49 EDT 25th September 2018 | BioPortfolio

Sequoia Sciences, an emerging leader in drug discovery, utilizes proprietary chemistry procedures and innovative technologies. Through internal research programs and collaborations with other drug discovery companies, our goal is to significantly increase the discovery rate of novel, drug-like compounds. On the basis of our current successes, we estimate that our rate of discovery of compounds with novel chemical structures will exceed 100 compounds annually.Sequoia’s proprietary methods and technologies are focused in the following areas:
1. Producing libraries of novel chemical compounds
2. Applying our advanced chemistry technologies for innovative uses
3. Discovering novel antibacterial compounds


1912 Innerbelt Business Center Drive
St. Louis
United States of America


Phone: 314-373-5181
Fax: 314-373-5186

News Articles [621 Associated News Articles listed on BioPortfolio]

First Interim Analysis in SEQUOIA Phase 3 Pancreatic Cancer Study

CancerConnect News: The first interim analysis of the SEQUOIA clinical study evaluating the novel immunotherapy drug pegilodecakin in patients with […] The post First Interim Analysis in SEQUOIA...

Sequoia Project Revises National Patient Matching Framework

Rajiv LeventhalThe nonprofit Sequoia Project, an industry advocate for nationwide interoperability, has released a revised national patient matching framework.

Sequoia Project to Make eHealth Exchange, Carequality Distinct Subsidiaries

David RathsThe nonprofit Sequoia Project announce May 10 that it will shift its corporate structure this summer to more clearly delineate two distinct subsidiaries; one for eHealth Exchange and one fo...

The Sequoia Project Developing Nationwide Health IT Disaster Response Platform

Heather LandiThe Sequoia Project is developing a nationwide deployment plan for the health IT disaster response platform known as the Patient Unified Lookup System for Emergencies (PULSE).

Refuge Biotechnologies Closes $25 Million Series B from Chinese Investors

Refuge Biotechnologies, a cell therapy company based in California bay area, received $25 million series B. The round was led by 3SBio and Sequoia China and followed by new investors Danhua Capital (D...

Sequoia leads Cortexyme's $76M series B

Sequoia China leads seed round for next-gen T cell therapy play

Allergan (AGN) Abicipar SEQUOIA & CEDAR Phase 3 Study Results - Slideshow

Clinical Trials [189 Associated Clinical Trials listed on BioPortfolio]

M-learning to Improve Professional Competencies in Health Sciences

The aim of this study is to investigate whether a mobile application is useful for improving knowledge about professional competencies in students enrolled in Health Sciences degrees.

Cognitive Rehabilitation With C8 Sciences

C8 sciences program is a cognitive training program mainly developed for the students, and the effectiveness is well established. The aim of this trial is to assess clinical efficacy of th...

A Study of Sofosbuvir From Heterosofir 400 mg F.C.T (Pharmed Healthcare, Egypt) & Sovaldi 400 mg F.C.T ( Gilead Sciences, Ireland)

Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Sofosbuvir from Heterosofir 400 mg F.C.T (Pharmed Healthcare Co., Egypt) versus S...

The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia

The purpose of this study is to evaluate that whether the AML (acute myeloid leukemia)-CAMS (Chinese Academy of Medical Sciences)-2016 regimen, includes risk-stratified therapy and the use...

A Bio-equivalence Study of Sofosbuvir From Sofodelevier 400 mg Film Coated Tablets (Al-debeiky Pharma, Egypt) Versus Sovaldi 400 mg Tablets (Gilead Sciences, Canada)

Comparative randomized, single dose, three way three sequence two treatment partial replicate crossover open-label study to determine the bioequivalence of Sofosbuvir from Sofodelevier 400...

Companies [1075 Associated Companies listed on BioPortfolio]

Sequoia Sciences, Inc.

Sequoia Sciences, an emerging leader in drug discovery, utilizes proprietary chemistry procedures and innovative technologies. Through internal research programs and collaborations with other drug dis...

Sequoia Pharmaceuticals, Inc.

Sequoia Pharmaceuticals discovers and develops revolutionary new treatments for viral diseases including HIV/AIDS and HCV-induced hepatitis with a focus on the growing global problem of drug-resistant...

Sequoia Hospital

DVS Sciences, Inc.

DVS Sciences is a life sciences technology company that has developed and manufactures a novel technology for highly multiplexed analysis of single cells. DVS Sciences has an R&D ...

Cambridge Epigenetix

Cambridge Epigenetix’s mission is to improve health through the routine measurement of the epigenome. Cambridge Epigenetix utilizes innovative technologies, often based on fu...

More Information about "Sequoia Sciences, Inc." on BioPortfolio

We have published hundreds of Sequoia Sciences, Inc. news stories on BioPortfolio along with dozens of Sequoia Sciences, Inc. Clinical Trials and PubMed Articles about Sequoia Sciences, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sequoia Sciences, Inc. Companies in our database. You can also find out about relevant Sequoia Sciences, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Corporate Database Quicklinks

Searches Linking to this Company Record